{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T09:25:14Z","timestamp":1795166714811,"version":"4.10.3"},"reference-count":76,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>6-mercaptopurine (6-MP) serves as the backbone in the maintenance regimens of acute lymphoblastic leukemia (ALL). We aimed to evaluate the influence of NUDT15 gene polymorphism on the risk of myelosupression, hepatotoxicity and interruption of 6-MP, as well as treatment efficacy and dose of 6-MP in ALL patients. A total of 24 studies with 3,374 patients were included in this meta-analysis. We found 9-fold higher risk of 6-MP induced leukopenia (odds ratio [OR] =9.00, 95% confidence interval [CI]: 3.73-21.74) and 2.5-fold higher risk of 6-MP-induced neutropenia (OR=2.52, 95% CI: 1.72-3.69) for NUDT15 c.415C&gt;T variant carriers in the dominant model. Moreover, we found that the dose intensity of 6-MP in ALL patients with one NUDT15 c.415C&gt;T variant alleles (CT) was 19% less than that in wild-type patients (CC) (mean differences: 19.43%, 95% CI: -25.36 to -13.51). The tolerable dose intensity of 6-MP in NUDT15 c.415C&gt;T homozygote variant (TT) and heterozygote variant (CT) carriers was 49% and 15% less than that in wild-type patients, respectively. The NUDT15 c.415C&gt;T variant group (CT+TT) had seven times (OR=6.98, 95% CI: 2.83-17.22) higher risk of developing 6-MP intolerance than the CC group. However, NUDT15 c.415C&gt;T polymorphism did not appear significantly associated with hepatotoxicity, treatment interruption or relapse incidence. We concluded that NUDT15 c.415C&gt;T was a good predictor for 6-MP-induced myelosuppression in ALL patients. The dose intensity of 6-MP in ALL patients with NUDT15 c.415C&gt;T variants was significantly lower than that in wild-type patients. This research provided a basis for further investigation into relations between NUDT15 gene and adverse reaction, treatment efficacy and dose intensity of 6-MP.<\/jats:p>","DOI":"10.3324\/haematol.2023.282761","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T03:05:57Z","timestamp":1696475157000},"page":"1053-1068","source":"Crossref","is-referenced-by-count":10,"title":["Association of &lt;i&gt;NUDT15&lt;\/i&gt; gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis"],"prefix":"10.3324","volume":"109","author":[{"given":"Shan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"59230","doi-asserted-by":"crossref","unstructured":"Al Ustwani O, Gupta N, Bakhribah H, Griffiths E, Wang E, Wetzler M. Clinical updates in adult acute lymphoblastic leukemia. Crit Rev Oncol Hematol. 2016; 99:189-199.","DOI":"10.1016\/j.critrevonc.2015.12.007"},{"key":"59231","doi-asserted-by":"crossref","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008; 371(9617):1030-1043.","DOI":"10.1016\/S0140-6736(08)60457-2"},{"key":"59232","doi-asserted-by":"crossref","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539.","DOI":"10.3324\/haematol.2020.247031"},{"key":"59233","doi-asserted-by":"crossref","unstructured":"Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acutelymphoblastic leukemia: a SEER analysis. Sci Rep. 2014; 4:4227.","DOI":"10.1038\/srep04227"},{"key":"59234","doi-asserted-by":"crossref","unstructured":"Teachey DT, Hunger SP, Loh ML. Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. Blood. 2021; 137(2):168-177.","DOI":"10.1182\/blood.2020007702"},{"key":"59235","doi-asserted-by":"crossref","unstructured":"Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022; 36(7):1749-1758.","DOI":"10.1038\/s41375-022-01591-4"},{"key":"59236","doi-asserted-by":"crossref","unstructured":"Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015; 29(4):243-249.","DOI":"10.1016\/j.blre.2015.01.001"},{"key":"59237","doi-asserted-by":"crossref","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine\/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014; 36(7):503-517.","DOI":"10.1097\/MPH.0000000000000206"},{"key":"59238","doi-asserted-by":"crossref","unstructured":"Ebbesen MS, Nersting J, Jacobsen JH. Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes. J Clin Pharmacol. 2013; 53(6):670-674.","DOI":"10.1002\/jcph.81"},{"key":"59239","doi-asserted-by":"crossref","unstructured":"Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol. 2010; 79(9):1211-1220.","DOI":"10.1016\/j.bcp.2010.01.006"},{"key":"59240","doi-asserted-by":"crossref","unstructured":"Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol. 2018; 53(2):172-180.","DOI":"10.1007\/s00535-017-1416-0"},{"key":"59241","doi-asserted-by":"crossref","unstructured":"Evans WE, Hon YY, Bomgaars L. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001; 19(8):2293-2301.","DOI":"10.1200\/JCO.2001.19.8.2293"},{"key":"59242","doi-asserted-by":"crossref","unstructured":"Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990; 336(8709):225-229.","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"59243","doi-asserted-by":"crossref","unstructured":"Relling MV, Hancock ML, Rivera GK. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999; 91(23):2001-2008.","DOI":"10.1093\/jnci\/91.23.2001"},{"key":"59244","doi-asserted-by":"crossref","unstructured":"Relling MV, Gardner EE, Sandborn WJ. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013; 93(4):324-325.","DOI":"10.1038\/clpt.2013.4"},{"key":"59245","doi-asserted-by":"crossref","unstructured":"Schmiegelow K, Forestier E, Kristinsson J. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia. 2009; 23(3):557-564.","DOI":"10.1038\/leu.2008.316"},{"key":"59246","doi-asserted-by":"crossref","unstructured":"Collie-Duguid ES, Pritchard SC, Powrie RH. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999; 9(1):37-42.","DOI":"10.1097\/00008571-199902000-00006"},{"key":"59247","doi-asserted-by":"crossref","unstructured":"Bhatia S, Landier W, Hageman L. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Blood. 2014; 124(15):2345-2353.","DOI":"10.1182\/blood-2014-01-552166"},{"key":"59248","doi-asserted-by":"crossref","unstructured":"Takatsu N, Matsui T, Murakami Y. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009; 24(7):1258-1264.","DOI":"10.1111\/j.1440-1746.2009.05917.x"},{"key":"59249","doi-asserted-by":"crossref","unstructured":"Moriyama T, Nishii R, Perez-Andreu V. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016; 48(4):367-373.","DOI":"10.1038\/ng.3508"},{"key":"59250","doi-asserted-by":"crossref","unstructured":"Yang JJ, Landier W, Yang W. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015; 33(11):1235-1242.","DOI":"10.1200\/JCO.2014.59.4671"},{"key":"59251","doi-asserted-by":"crossref","unstructured":"Yang SK, Hong M, Baek J. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nature Genet. 2014; 46(9):1017-1020.","DOI":"10.1038\/ng.3060"},{"key":"59252","doi-asserted-by":"crossref","unstructured":"Singh M, Bhatia P, Khera S, Trehan A. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia. Leuk Res. 2017; 62:17-22.","DOI":"10.1016\/j.leukres.2017.09.012"},{"key":"59253","doi-asserted-by":"crossref","unstructured":"Correa-Jimenez O, Yunis JJ, Linares-Ballesteros A, Sarmiento-Urbina I. Susceptibility to thiopurine toxicity by TPMT and NUDT15 variants in Colombian children with acute lymphoblastic leukemia. Colomb Med (Cali). 2021; 52(3):e2074569.","DOI":"10.25100\/cm.v52i3.4569"},{"key":"59254","doi-asserted-by":"crossref","unstructured":"Fan POL, Leung KT, Chan KYY. ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in chinese patients with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022; 39(3):254-266.","DOI":"10.1080\/08880018.2021.1973628"},{"key":"59255","doi-asserted-by":"crossref","unstructured":"Mao XY, Yin RX, Sun GY. Effects of TPMT, NUDT15, and ITPA genetic variants on 6-mercaptopurine toxicity for pediatric patients with acute lymphoblastic leukemia in Yunnan of China. Front Pediatr. 2021; 9:719803.","DOI":"10.3389\/fped.2021.719803"},{"key":"59256","doi-asserted-by":"crossref","unstructured":"Pai AA, Mohan A, Benjamin ESB. NUDT15 c.415C&gt;T polymorphism predicts 6-MP induced early myelotoxicity in patients with acute lymphoblastic leukemia undergoing maintenance therapy. Pharmgenomics Pers Med. 2021; 14:1303-1313.","DOI":"10.2147\/PGPM.S325813"},{"key":"59257","doi-asserted-by":"crossref","unstructured":"Cargnin S, Genazzani AA, Canonico PL, Terrazzin S. Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. Pharmacol Res. 2018; 135:102-111.","DOI":"10.1016\/j.phrs.2018.07.021"},{"key":"59258","doi-asserted-by":"crossref","unstructured":"Khaeso K, Udayachalerm S, Komvilaisak P. Meta-analysis of NUDT15 genetic polymorphism on thiopurine-induced myelosuppression in Asian populations. Front Pharmacol. 2021; 12:784712.","DOI":"10.3389\/fphar.2021.784712"},{"key":"59259","doi-asserted-by":"crossref","unstructured":"van Gennep S, Kont\u00e9 K, Meijer B. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther. 2019; 50(5):484-506.","DOI":"10.1111\/apt.15403"},{"key":"59260","doi-asserted-by":"crossref","unstructured":"Wang R, Liu B, Li J. Association between the c.415C&gt;T, c.52G&gt;A, and 36_37insGGAGTC polymorphisms of NUDT 15 and thiopurine-induced leukopenia, thiopurine intolerance, and severe hair loss: an updated meta-analysis. Drug Des Devel Ther. 2019; 13:2729-2744.","DOI":"10.2147\/DDDT.S210512"},{"key":"59261","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"59262","unstructured":"Wells GA, Shea B, O\u2019Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2009. Publisher Full Text|"},{"key":"59263","doi-asserted-by":"crossref","unstructured":"Cao M, Yin D, Qin Y. Screening of novel pharmacogenetic candidates for mercaptopurine-induced toxicity in patients with acute lymphoblastic leukemia. Front Pharmacol. 2020; 11:267.","DOI":"10.3389\/fphar.2020.00267"},{"key":"59264","unstructured":"Li H, Shen J, Ru Y, Tu C, Li Y, Ren D. Association between rs116855232 gene polymorphisms and mercaptopurine-induced adverse reactions in children with acute lymphoblastic leukemia. Chin J Pharmacoepidemiol. 2021; 30(9):596-600."},{"key":"59265","doi-asserted-by":"crossref","unstructured":"Liang DC, Yang CP, Liu HC. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016; 16(6):536-539.","DOI":"10.1038\/tpj.2015.75"},{"key":"59266","unstructured":"Liu JW, X. Association between polymorphism of NDUT15 gene and leucopenia induced by 6-mercaptopurine in children with acute lymphoblastic leukemia. J Clin Pediatr. 2018; 36(2):113-116."},{"key":"59267","unstructured":"Wang J, Wang X, Hao G, Cheng Y, Lu H, Suo T. Relationship between NUDT15 gene polymorphism and tolerance to treatment with 6-mercaptopurinein children with acute lymphoblastic leukemia. J Leuk Lymphoma. 2022; 31(5):286-289."},{"key":"59268","unstructured":"Wang X, Wang W. Association between polymorphism of NUDT15 gene and hepatotoxicity induced by 6-MP in children with acute lymphoblastic leukemia. Chin J Med Genet. 2021; 38(12):1258-1261."},{"key":"59269","doi-asserted-by":"crossref","unstructured":"Zhou H, Li L, Yang P. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?. BMC Cancer. 2018; 18(1):516.","DOI":"10.1186\/s12885-018-4398-2"},{"key":"59270","doi-asserted-by":"crossref","unstructured":"Zhu Y, Yin D, Su Y. Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia. Haematologica. 2018; 103(7):e293-e295.","DOI":"10.3324\/haematol.2018.187658"},{"key":"59271","doi-asserted-by":"crossref","unstructured":"Suzuki H, Fukushima H, Suzuki R. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. J Hum Genet. 2016; 61(9):797-801.","DOI":"10.1038\/jhg.2016.55"},{"key":"59272","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Kato M, Hasegawa D. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015; 171(1):109-115.","DOI":"10.1111\/bjh.13518"},{"key":"59273","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Nakadate H, Kondoh K, Nakamura K, Koh K, Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018; 18(2):275-280.","DOI":"10.1038\/tpj.2017.12"},{"key":"59274","doi-asserted-by":"crossref","unstructured":"Choi R, Sohn I, Kim MJ. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2019; 85(7):1585-1597.","DOI":"10.1111\/bcp.13943"},{"key":"59275","doi-asserted-by":"crossref","unstructured":"Kim H, Seo H, Park Y. APEX1 polymorphism and mercaptopurine-related early onset neutropenia in pediatric acute lymphoblastic leukemia. Cancer Res Treat. 2018; 50(3):823-834.","DOI":"10.4143\/crt.2017.351"},{"key":"59276","doi-asserted-by":"crossref","unstructured":"Lee JM, Shim YJ, Kim DH, Jung N, Ha JS. The effect of NUDT15, TPMT, APEX1, and ITPA genetic variations on mercaptopurine treatment of pediatric acute lymphoblastic leukemia. Children (Basel). 2021; 8(3):224.","DOI":"10.3390\/children8030224"},{"key":"59277","doi-asserted-by":"crossref","unstructured":"Buaboonnam J, Sripatanatadasakul P, Treesucon A. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia. Pediatr Int. 2019; 61(8):754-758.","DOI":"10.1111\/ped.13905"},{"key":"59278","doi-asserted-by":"crossref","unstructured":"Chiengthong K, Ittiwut C, Muensri S. NUDT15 c.415C&gt;T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica. 2016; 101(1):e24-26.","DOI":"10.3324\/haematol.2015.134775"},{"key":"59279","doi-asserted-by":"crossref","unstructured":"Khaeso K, Komvilaisak P, Chainansamit SO. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine. Drug Metab Pharmacokinet. 2022; 43:100436.","DOI":"10.1016\/j.dmpk.2021.100436"},{"key":"59280","doi-asserted-by":"crossref","unstructured":"Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019; 83(2):341-348.","DOI":"10.1007\/s00280-018-3732-3"},{"key":"59281","doi-asserted-by":"crossref","unstructured":"Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK. ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in Middle Eastern children with acute lymphoblastic leukemia. Front Pharmacol. 2019; 10:916.","DOI":"10.3389\/fphar.2019.00916"},{"key":"59282","doi-asserted-by":"crossref","unstructured":"Brown PA, Shah B, Advani A. Acute lymphoblastic leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021; 19(9):1079-1109.","DOI":"10.6004\/jnccn.2021.0042"},{"key":"59283","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Saito Y. Importance of NUDT15 polymorphisms in thiopurine treatments. J Pers Med. 2021; 11(8):778.","DOI":"10.3390\/jpm11080778"},{"key":"59284","doi-asserted-by":"crossref","unstructured":"Broekman M, Coenen MJH, Wanten GJ. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Aliment Pharmacol Ther. 2017; 46(10):953-963.","DOI":"10.1111\/apt.14323"},{"key":"59285","doi-asserted-by":"crossref","unstructured":"Kojima Y, Hirotsu Y, Omata W. Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. World J Gastroenterol. 2018; 24(4):511-518.","DOI":"10.3748\/wjg.v24.i4.511"},{"key":"59286","doi-asserted-by":"crossref","unstructured":"Tsuchiya A, Aomori T, Sakamoto M. Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. Pharmazie. 2017; 72(1):22-28.","DOI":"10.31083\/ph.2017.6799"},{"key":"59287","doi-asserted-by":"crossref","unstructured":"Kim SY, Shin JH, Park JS. NUDT15 p.R139C variant is common and strongly associated with azathioprine-induced early leukopenia and severe alopecia in Korean patients with various neurological diseases. J Neurol Sci. 2017; 378:64-68.","DOI":"10.1016\/j.jns.2017.04.041"},{"key":"59288","doi-asserted-by":"crossref","unstructured":"Fan X, Yin D, Men R, Xu H, Yang L. NUDT15 polymorphism confer increased susceptibility to thiopurine-induced leukopenia in patients with autoimmune hepatitis and related cirrhosis. Front Pharmacol. 2019; 10:346.","DOI":"10.3389\/fphar.2019.00346"},{"key":"59289","doi-asserted-by":"crossref","unstructured":"Sato T, Takagawa T, Kakuta Y. NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest Res. 2017; 15(3):328-337.","DOI":"10.5217\/ir.2017.15.3.328"},{"key":"59290","doi-asserted-by":"crossref","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019; 105(5):1095-1105.","DOI":"10.1002\/cpt.1304"},{"key":"59291","doi-asserted-by":"crossref","unstructured":"Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther. 2004; 75(4):274-281.","DOI":"10.1016\/S0009-9236(03)00743-4"},{"key":"59292","unstructured":"Hao QS, Wang Z, Fang QY. Effect of genetic polymorphism of TPMT and NUDT15 on the tolerance of 6-mercaptopurine therapy in adult acute lymphoblastic leukemia. Chin J Hematol. 2021; 42(11):911-916."},{"key":"59293","doi-asserted-by":"crossref","unstructured":"Zhou Y, Wang L, Zhai XY. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2020; 86(8):1519-1527.","DOI":"10.1111\/bcp.14258"},{"key":"59294","doi-asserted-by":"crossref","unstructured":"Bhatia S, Landier W, Hageman L. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children\u2019s oncology group study. JAMA Oncol. 2015; 1(3):287-295.","DOI":"10.1001\/jamaoncol.2015.0245"},{"key":"59295","doi-asserted-by":"crossref","unstructured":"Li B, Brady SW, Ma X. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020; 135(1):41-55.","DOI":"10.1182\/blood.2019002220"},{"key":"59296","doi-asserted-by":"crossref","unstructured":"Li B, Li H, Bai Y. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med. 2015; 21(6):563-571.","DOI":"10.1038\/nm.3840"},{"key":"59297","doi-asserted-by":"crossref","unstructured":"Nielsen SN, Toksvang LN, Grell K. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Cancer Chemother Pharmacol. 2021; 88(2):271-279.","DOI":"10.1007\/s00280-021-04281-7"},{"key":"59298","doi-asserted-by":"crossref","unstructured":"Mullighan CG. Mutant PRPS1: a new therapeutic target in relapsed acute lymphoblastic leukemia. Nat Med. 2015; 21(6):553-554.","DOI":"10.1038\/nm.3876"},{"key":"59299","doi-asserted-by":"crossref","unstructured":"Dieck CL, Tzoneva G, Forouhar F. Structure and mechanisms of NT5C2 mutations driving thiopurine resistance in relapsed lymphoblastic leukemia. Cancer Cell. 2018; 34(1):136-147.e6.","DOI":"10.1016\/j.ccell.2018.06.003"},{"key":"59300","doi-asserted-by":"crossref","unstructured":"Somazu S, Tanaka Y, Tamai M. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells. J Cell Mol Med. 2021; 25(22):10521-10533.","DOI":"10.1111\/jcmm.16981"},{"key":"59301","doi-asserted-by":"crossref","unstructured":"Nishii R, Moriyama T, Janke LJ. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018; 131(22):2466-2474.","DOI":"10.1182\/blood-2017-11-815506"},{"key":"59302","doi-asserted-by":"crossref","unstructured":"Wei X, Zhuang J, Li N. NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China. Int J Hematol. 2022; 115(2):278-286.","DOI":"10.1007\/s12185-021-03237-0"},{"key":"59303","doi-asserted-by":"crossref","unstructured":"Jena A, Jha DK, Kumar-M P. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2021; 14(4):491-501.","DOI":"10.1080\/17512433.2021.1900729"},{"key":"59304","doi-asserted-by":"crossref","unstructured":"Liu Y, Meng Y, Wang L, Liu Z, Li J, Dong W. Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis. Onco Targets Ther. 2018; 11:8309-8317.","DOI":"10.2147\/OTT.S177007"},{"key":"59305","doi-asserted-by":"crossref","unstructured":"Chang JY, Park SJ, Jung ES. Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020; 18(9):2010-2018.","DOI":"10.1016\/j.cgh.2019.08.034"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282761\/76157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282761\/76764","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11288\/76157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:01Z","timestamp":1794045901000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282761","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}